nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT1A9—Nateglinide—type 2 diabetes mellitus	0.104	0.16	CbGbCtD
Tapentadol—UGT2B7—Losartan—type 2 diabetes mellitus	0.0609	0.0933	CbGbCtD
Tapentadol—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.0325	0.0498	CbGbCtD
Tapentadol—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0318	0.0487	CbGbCtD
Tapentadol—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0291	0.0445	CbGbCtD
Tapentadol—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.0276	0.0423	CbGbCtD
Tapentadol—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.0276	0.0423	CbGbCtD
Tapentadol—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.027	0.0414	CbGbCtD
Tapentadol—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.0255	0.0391	CbGbCtD
Tapentadol—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.0246	0.0377	CbGbCtD
Tapentadol—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.023	0.0352	CbGbCtD
Tapentadol—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.023	0.0352	CbGbCtD
Tapentadol—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.0212	0.0325	CbGbCtD
Tapentadol—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.021	0.0322	CbGbCtD
Tapentadol—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.0205	0.0314	CbGbCtD
Tapentadol—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0194	0.0297	CbGbCtD
Tapentadol—CYP2C9—Valsartan—type 2 diabetes mellitus	0.0187	0.0287	CbGbCtD
Tapentadol—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.0174	0.0267	CbGbCtD
Tapentadol—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.0167	0.0256	CbGbCtD
Tapentadol—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0159	0.0244	CbGbCtD
Tapentadol—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0153	0.0234	CbGbCtD
Tapentadol—CYP2C19—Glyburide—type 2 diabetes mellitus	0.0141	0.0217	CbGbCtD
Tapentadol—CYP2C19—Losartan—type 2 diabetes mellitus	0.0129	0.0198	CbGbCtD
Tapentadol—CYP2C9—Glyburide—type 2 diabetes mellitus	0.0118	0.018	CbGbCtD
Tapentadol—CYP2C9—Losartan—type 2 diabetes mellitus	0.0108	0.0165	CbGbCtD
Tapentadol—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00298	0.201	CbGeAlD
Tapentadol—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.002	0.135	CbGeAlD
Tapentadol—HTR3A—nerve—type 2 diabetes mellitus	0.00168	0.113	CbGeAlD
Tapentadol—OPRM1—nerve—type 2 diabetes mellitus	0.00154	0.104	CbGeAlD
Tapentadol—SLC6A2—nerve—type 2 diabetes mellitus	0.00113	0.0759	CbGeAlD
Tapentadol—UGT1A9—kidney—type 2 diabetes mellitus	0.000977	0.0659	CbGeAlD
Tapentadol—HTR3A—islet of Langerhans—type 2 diabetes mellitus	0.000812	0.0548	CbGeAlD
Tapentadol—UGT2B7—kidney—type 2 diabetes mellitus	0.000788	0.0531	CbGeAlD
Tapentadol—OPRD1—kidney—type 2 diabetes mellitus	0.000773	0.0521	CbGeAlD
Tapentadol—Rivastigmine—CYP3A4—type 2 diabetes mellitus	0.000727	0.529	CrCbGaD
Tapentadol—Phenylephrine—CYP1A2—type 2 diabetes mellitus	0.000647	0.471	CrCbGaD
Tapentadol—UGT1A9—liver—type 2 diabetes mellitus	0.000618	0.0417	CbGeAlD
Tapentadol—UGT2B7—liver—type 2 diabetes mellitus	0.000498	0.0336	CbGeAlD
Tapentadol—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000288	0.0194	CbGeAlD
Tapentadol—CYP2C19—liver—type 2 diabetes mellitus	0.000229	0.0155	CbGeAlD
Tapentadol—CYP2D6—kidney—type 2 diabetes mellitus	0.000211	0.0142	CbGeAlD
Tapentadol—Nervousness—Losartan—type 2 diabetes mellitus	0.000184	0.000842	CcSEcCtD
Tapentadol—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000184	0.000842	CcSEcCtD
Tapentadol—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000183	0.00084	CcSEcCtD
Tapentadol—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000183	0.000839	CcSEcCtD
Tapentadol—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000183	0.000838	CcSEcCtD
Tapentadol—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000182	0.000836	CcSEcCtD
Tapentadol—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000182	0.000832	CcSEcCtD
Tapentadol—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000181	0.000828	CcSEcCtD
Tapentadol—Headache—Pioglitazone—type 2 diabetes mellitus	0.00018	0.000827	CcSEcCtD
Tapentadol—Syncope—Irbesartan—type 2 diabetes mellitus	0.00018	0.000826	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.00018	0.000825	CcSEcCtD
Tapentadol—Visual impairment—Ramipril—type 2 diabetes mellitus	0.00018	0.000823	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000179	0.000822	CcSEcCtD
Tapentadol—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000179	0.000821	CcSEcCtD
Tapentadol—Nausea—Glipizide—type 2 diabetes mellitus	0.000179	0.000819	CcSEcCtD
Tapentadol—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000178	0.000818	CcSEcCtD
Tapentadol—Hypotension—Valsartan—type 2 diabetes mellitus	0.000178	0.000818	CcSEcCtD
Tapentadol—Vision blurred—Losartan—type 2 diabetes mellitus	0.000178	0.000817	CcSEcCtD
Tapentadol—CYP2C9—liver—type 2 diabetes mellitus	0.000178	0.012	CbGeAlD
Tapentadol—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000178	0.000815	CcSEcCtD
Tapentadol—Constipation—Gliclazide—type 2 diabetes mellitus	0.000178	0.000814	CcSEcCtD
Tapentadol—Tremor—Losartan—type 2 diabetes mellitus	0.000177	0.000812	CcSEcCtD
Tapentadol—Rash—Glimepiride—type 2 diabetes mellitus	0.000177	0.000811	CcSEcCtD
Tapentadol—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000177	0.00081	CcSEcCtD
Tapentadol—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000177	0.00081	CcSEcCtD
Tapentadol—Rash—Sitagliptin—type 2 diabetes mellitus	0.000176	0.000808	CcSEcCtD
Tapentadol—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000176	0.000807	CcSEcCtD
Tapentadol—Headache—Glimepiride—type 2 diabetes mellitus	0.000176	0.000806	CcSEcCtD
Tapentadol—Cough—Irbesartan—type 2 diabetes mellitus	0.000175	0.000804	CcSEcCtD
Tapentadol—Headache—Sitagliptin—type 2 diabetes mellitus	0.000175	0.000803	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000174	0.000797	CcSEcCtD
Tapentadol—Agitation—Losartan—type 2 diabetes mellitus	0.000174	0.000797	CcSEcCtD
Tapentadol—Oedema—Metformin—type 2 diabetes mellitus	0.000174	0.000797	CcSEcCtD
Tapentadol—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000173	0.000794	CcSEcCtD
Tapentadol—Angioedema—Losartan—type 2 diabetes mellitus	0.000173	0.000792	CcSEcCtD
Tapentadol—Infection—Metformin—type 2 diabetes mellitus	0.000173	0.000792	CcSEcCtD
Tapentadol—Insomnia—Valsartan—type 2 diabetes mellitus	0.000173	0.000791	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000172	0.000788	CcSEcCtD
Tapentadol—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000171	0.000786	CcSEcCtD
Tapentadol—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000171	0.000785	CcSEcCtD
Tapentadol—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000171	0.000784	CcSEcCtD
Tapentadol—Shock—Metformin—type 2 diabetes mellitus	0.000171	0.000784	CcSEcCtD
Tapentadol—Insomnia—Orlistat—type 2 diabetes mellitus	0.000171	0.000782	CcSEcCtD
Tapentadol—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000171	0.000782	CcSEcCtD
Tapentadol—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000171	0.000781	CcSEcCtD
Tapentadol—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000171	0.000781	CcSEcCtD
Tapentadol—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.00017	0.00078	CcSEcCtD
Tapentadol—Vertigo—Losartan—type 2 diabetes mellitus	0.00017	0.000779	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.00017	0.000779	CcSEcCtD
Tapentadol—Somnolence—Valsartan—type 2 diabetes mellitus	0.00017	0.000778	CcSEcCtD
Tapentadol—Syncope—Losartan—type 2 diabetes mellitus	0.00017	0.000778	CcSEcCtD
Tapentadol—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000169	0.000776	CcSEcCtD
Tapentadol—Skin disorder—Metformin—type 2 diabetes mellitus	0.000169	0.000774	CcSEcCtD
Tapentadol—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000168	0.000771	CcSEcCtD
Tapentadol—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000168	0.00077	CcSEcCtD
Tapentadol—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000168	0.00077	CcSEcCtD
Tapentadol—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000168	0.00077	CcSEcCtD
Tapentadol—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000167	0.000767	CcSEcCtD
Tapentadol—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000167	0.000767	CcSEcCtD
Tapentadol—Palpitations—Losartan—type 2 diabetes mellitus	0.000167	0.000766	CcSEcCtD
Tapentadol—Nausea—Glimepiride—type 2 diabetes mellitus	0.000167	0.000764	CcSEcCtD
Tapentadol—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000166	0.000762	CcSEcCtD
Tapentadol—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000166	0.000761	CcSEcCtD
Tapentadol—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000166	0.000761	CcSEcCtD
Tapentadol—Asthenia—Glyburide—type 2 diabetes mellitus	0.000166	0.000761	CcSEcCtD
Tapentadol—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000166	0.000761	CcSEcCtD
Tapentadol—Cough—Losartan—type 2 diabetes mellitus	0.000165	0.000757	CcSEcCtD
Tapentadol—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000165	0.000757	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000165	0.000755	CcSEcCtD
Tapentadol—Fatigue—Valsartan—type 2 diabetes mellitus	0.000165	0.000754	CcSEcCtD
Tapentadol—Oedema—Irbesartan—type 2 diabetes mellitus	0.000164	0.000752	CcSEcCtD
Tapentadol—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000164	0.000752	CcSEcCtD
Tapentadol—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000164	0.000752	CcSEcCtD
Tapentadol—Pruritus—Glyburide—type 2 diabetes mellitus	0.000164	0.00075	CcSEcCtD
Tapentadol—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000163	0.000748	CcSEcCtD
Tapentadol—Constipation—Valsartan—type 2 diabetes mellitus	0.000163	0.000748	CcSEcCtD
Tapentadol—Infection—Irbesartan—type 2 diabetes mellitus	0.000163	0.000747	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000163	0.000746	CcSEcCtD
Tapentadol—Fatigue—Orlistat—type 2 diabetes mellitus	0.000163	0.000745	CcSEcCtD
Tapentadol—Hypotension—Metformin—type 2 diabetes mellitus	0.000162	0.000744	CcSEcCtD
Tapentadol—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000162	0.000743	CcSEcCtD
Tapentadol—Shock—Irbesartan—type 2 diabetes mellitus	0.000161	0.00074	CcSEcCtD
Tapentadol—Arthralgia—Losartan—type 2 diabetes mellitus	0.000161	0.000738	CcSEcCtD
Tapentadol—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000161	0.000738	CcSEcCtD
Tapentadol—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000161	0.000737	CcSEcCtD
Tapentadol—Anxiety—Losartan—type 2 diabetes mellitus	0.000161	0.000736	CcSEcCtD
Tapentadol—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.00016	0.000734	CcSEcCtD
Tapentadol—Rash—Bromocriptine—type 2 diabetes mellitus	0.00016	0.000731	CcSEcCtD
Tapentadol—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000159	0.000731	CcSEcCtD
Tapentadol—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000159	0.00073	CcSEcCtD
Tapentadol—Tension—Ramipril—type 2 diabetes mellitus	0.000159	0.00073	CcSEcCtD
Tapentadol—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000159	0.000727	CcSEcCtD
Tapentadol—Headache—Bromocriptine—type 2 diabetes mellitus	0.000159	0.000727	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000158	0.000726	CcSEcCtD
Tapentadol—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000158	0.000726	CcSEcCtD
Tapentadol—Nervousness—Ramipril—type 2 diabetes mellitus	0.000158	0.000722	CcSEcCtD
Tapentadol—Dry mouth—Losartan—type 2 diabetes mellitus	0.000158	0.000722	CcSEcCtD
Tapentadol—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000156	0.000715	CcSEcCtD
Tapentadol—Confusional state—Losartan—type 2 diabetes mellitus	0.000156	0.000713	CcSEcCtD
Tapentadol—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000155	0.000712	CcSEcCtD
Tapentadol—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000155	0.00071	CcSEcCtD
Tapentadol—Somnolence—Metformin—type 2 diabetes mellitus	0.000155	0.000708	CcSEcCtD
Tapentadol—Oedema—Losartan—type 2 diabetes mellitus	0.000154	0.000708	CcSEcCtD
Tapentadol—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000154	0.000708	CcSEcCtD
Tapentadol—Infection—Losartan—type 2 diabetes mellitus	0.000153	0.000703	CcSEcCtD
Tapentadol—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000153	0.000703	CcSEcCtD
Tapentadol—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000153	0.000702	CcSEcCtD
Tapentadol—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000153	0.000701	CcSEcCtD
Tapentadol—Tremor—Ramipril—type 2 diabetes mellitus	0.000152	0.000697	CcSEcCtD
Tapentadol—Shock—Losartan—type 2 diabetes mellitus	0.000152	0.000696	CcSEcCtD
Tapentadol—Urticaria—Valsartan—type 2 diabetes mellitus	0.000152	0.000695	CcSEcCtD
Tapentadol—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000151	0.000694	CcSEcCtD
Tapentadol—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000151	0.000693	CcSEcCtD
Tapentadol—Tachycardia—Losartan—type 2 diabetes mellitus	0.000151	0.000691	CcSEcCtD
Tapentadol—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00015	0.000689	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.00015	0.000688	CcSEcCtD
Tapentadol—Fatigue—Metformin—type 2 diabetes mellitus	0.00015	0.000687	CcSEcCtD
Tapentadol—Urticaria—Orlistat—type 2 diabetes mellitus	0.00015	0.000687	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000149	0.000685	CcSEcCtD
Tapentadol—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000149	0.000684	CcSEcCtD
Tapentadol—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000149	0.000683	CcSEcCtD
Tapentadol—Agitation—Ramipril—type 2 diabetes mellitus	0.000149	0.000683	CcSEcCtD
Tapentadol—Constipation—Metformin—type 2 diabetes mellitus	0.000149	0.000681	CcSEcCtD
Tapentadol—Angioedema—Ramipril—type 2 diabetes mellitus	0.000148	0.000679	CcSEcCtD
Tapentadol—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000147	0.000675	CcSEcCtD
Tapentadol—Vomiting—Glyburide—type 2 diabetes mellitus	0.000147	0.000674	CcSEcCtD
Tapentadol—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000147	0.000674	CcSEcCtD
Tapentadol—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000146	0.00067	CcSEcCtD
Tapentadol—Rash—Glyburide—type 2 diabetes mellitus	0.000146	0.000669	CcSEcCtD
Tapentadol—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000146	0.000668	CcSEcCtD
Tapentadol—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000146	0.000668	CcSEcCtD
Tapentadol—Vertigo—Ramipril—type 2 diabetes mellitus	0.000146	0.000668	CcSEcCtD
Tapentadol—Syncope—Ramipril—type 2 diabetes mellitus	0.000145	0.000667	CcSEcCtD
Tapentadol—Headache—Glyburide—type 2 diabetes mellitus	0.000145	0.000664	CcSEcCtD
Tapentadol—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000144	0.000662	CcSEcCtD
Tapentadol—Hypotension—Losartan—type 2 diabetes mellitus	0.000144	0.000661	CcSEcCtD
Tapentadol—Palpitations—Ramipril—type 2 diabetes mellitus	0.000143	0.000657	CcSEcCtD
Tapentadol—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000143	0.000657	CcSEcCtD
Tapentadol—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000143	0.000654	CcSEcCtD
Tapentadol—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000143	0.000653	CcSEcCtD
Tapentadol—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000142	0.000652	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000142	0.000649	CcSEcCtD
Tapentadol—Cough—Ramipril—type 2 diabetes mellitus	0.000142	0.000649	CcSEcCtD
Tapentadol—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000141	0.000648	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000141	0.000645	CcSEcCtD
Tapentadol—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000141	0.000645	CcSEcCtD
Tapentadol—Convulsion—Ramipril—type 2 diabetes mellitus	0.000141	0.000644	CcSEcCtD
Tapentadol—Constipation—Irbesartan—type 2 diabetes mellitus	0.00014	0.000643	CcSEcCtD
Tapentadol—Insomnia—Losartan—type 2 diabetes mellitus	0.00014	0.00064	CcSEcCtD
Tapentadol—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000139	0.000637	CcSEcCtD
Tapentadol—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000139	0.000635	CcSEcCtD
Tapentadol—Urticaria—Metformin—type 2 diabetes mellitus	0.000138	0.000633	CcSEcCtD
Tapentadol—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000138	0.000633	CcSEcCtD
Tapentadol—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000138	0.000631	CcSEcCtD
Tapentadol—Anxiety—Ramipril—type 2 diabetes mellitus	0.000138	0.000631	CcSEcCtD
Tapentadol—Nausea—Glyburide—type 2 diabetes mellitus	0.000137	0.00063	CcSEcCtD
Tapentadol—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000137	0.00063	CcSEcCtD
Tapentadol—Somnolence—Losartan—type 2 diabetes mellitus	0.000137	0.000629	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000137	0.000629	CcSEcCtD
Tapentadol—Asthenia—Valsartan—type 2 diabetes mellitus	0.000137	0.000628	CcSEcCtD
Tapentadol—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000136	0.000623	CcSEcCtD
Tapentadol—Asthenia—Orlistat—type 2 diabetes mellitus	0.000135	0.00062	CcSEcCtD
Tapentadol—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000135	0.00062	CcSEcCtD
Tapentadol—Pruritus—Valsartan—type 2 diabetes mellitus	0.000135	0.000619	CcSEcCtD
Tapentadol—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000135	0.000619	CcSEcCtD
Tapentadol—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000134	0.000615	CcSEcCtD
Tapentadol—CYP2D6—liver—type 2 diabetes mellitus	0.000134	0.00901	CbGeAlD
Tapentadol—Confusional state—Ramipril—type 2 diabetes mellitus	0.000134	0.000612	CcSEcCtD
Tapentadol—Pruritus—Orlistat—type 2 diabetes mellitus	0.000133	0.000612	CcSEcCtD
Tapentadol—Fatigue—Losartan—type 2 diabetes mellitus	0.000133	0.00061	CcSEcCtD
Tapentadol—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000132	0.000607	CcSEcCtD
Tapentadol—Oedema—Ramipril—type 2 diabetes mellitus	0.000132	0.000607	CcSEcCtD
Tapentadol—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000132	0.000605	CcSEcCtD
Tapentadol—Constipation—Losartan—type 2 diabetes mellitus	0.000132	0.000605	CcSEcCtD
Tapentadol—Rash—Gliclazide—type 2 diabetes mellitus	0.000131	0.0006	CcSEcCtD
Tapentadol—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000131	0.0006	CcSEcCtD
Tapentadol—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000131	0.000599	CcSEcCtD
Tapentadol—Urticaria—Irbesartan—type 2 diabetes mellitus	0.00013	0.000597	CcSEcCtD
Tapentadol—Shock—Ramipril—type 2 diabetes mellitus	0.00013	0.000597	CcSEcCtD
Tapentadol—Headache—Gliclazide—type 2 diabetes mellitus	0.00013	0.000597	CcSEcCtD
Tapentadol—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.00013	0.000595	CcSEcCtD
Tapentadol—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000129	0.000592	CcSEcCtD
Tapentadol—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000129	0.000592	CcSEcCtD
Tapentadol—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000129	0.000589	CcSEcCtD
Tapentadol—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000128	0.000587	CcSEcCtD
Tapentadol—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000127	0.000583	CcSEcCtD
Tapentadol—Dizziness—Valsartan—type 2 diabetes mellitus	0.000126	0.000579	CcSEcCtD
Tapentadol—Dizziness—Orlistat—type 2 diabetes mellitus	0.000125	0.000572	CcSEcCtD
Tapentadol—Asthenia—Metformin—type 2 diabetes mellitus	0.000125	0.000572	CcSEcCtD
Tapentadol—Hypotension—Ramipril—type 2 diabetes mellitus	0.000124	0.000567	CcSEcCtD
Tapentadol—Nausea—Gliclazide—type 2 diabetes mellitus	0.000123	0.000566	CcSEcCtD
Tapentadol—Pruritus—Metformin—type 2 diabetes mellitus	0.000123	0.000564	CcSEcCtD
Tapentadol—Urticaria—Losartan—type 2 diabetes mellitus	0.000123	0.000562	CcSEcCtD
Tapentadol—Vomiting—Valsartan—type 2 diabetes mellitus	0.000121	0.000556	CcSEcCtD
Tapentadol—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000121	0.000554	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000121	0.000553	CcSEcCtD
Tapentadol—Rash—Valsartan—type 2 diabetes mellitus	0.00012	0.000552	CcSEcCtD
Tapentadol—Dermatitis—Valsartan—type 2 diabetes mellitus	0.00012	0.000551	CcSEcCtD
Tapentadol—Vomiting—Orlistat—type 2 diabetes mellitus	0.00012	0.00055	CcSEcCtD
Tapentadol—Insomnia—Ramipril—type 2 diabetes mellitus	0.00012	0.000549	CcSEcCtD
Tapentadol—Headache—Valsartan—type 2 diabetes mellitus	0.00012	0.000548	CcSEcCtD
Tapentadol—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000119	0.000545	CcSEcCtD
Tapentadol—Rash—Orlistat—type 2 diabetes mellitus	0.000119	0.000545	CcSEcCtD
Tapentadol—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000119	0.000545	CcSEcCtD
Tapentadol—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000119	0.000545	CcSEcCtD
Tapentadol—Headache—Orlistat—type 2 diabetes mellitus	0.000118	0.000542	CcSEcCtD
Tapentadol—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000118	0.000541	CcSEcCtD
Tapentadol—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000118	0.000539	CcSEcCtD
Tapentadol—Somnolence—Ramipril—type 2 diabetes mellitus	0.000118	0.000539	CcSEcCtD
Tapentadol—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000117	0.000534	CcSEcCtD
Tapentadol—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000116	0.000532	CcSEcCtD
Tapentadol—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000115	0.000527	CcSEcCtD
Tapentadol—Dizziness—Metformin—type 2 diabetes mellitus	0.000115	0.000527	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000114	0.000524	CcSEcCtD
Tapentadol—Fatigue—Ramipril—type 2 diabetes mellitus	0.000114	0.000523	CcSEcCtD
Tapentadol—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000114	0.000521	CcSEcCtD
Tapentadol—Nausea—Valsartan—type 2 diabetes mellitus	0.000113	0.00052	CcSEcCtD
Tapentadol—Constipation—Ramipril—type 2 diabetes mellitus	0.000113	0.000519	CcSEcCtD
Tapentadol—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000112	0.000514	CcSEcCtD
Tapentadol—Nausea—Orlistat—type 2 diabetes mellitus	0.000112	0.000514	CcSEcCtD
Tapentadol—Asthenia—Losartan—type 2 diabetes mellitus	0.000111	0.000508	CcSEcCtD
Tapentadol—Vomiting—Metformin—type 2 diabetes mellitus	0.000111	0.000507	CcSEcCtD
Tapentadol—Rash—Metformin—type 2 diabetes mellitus	0.00011	0.000502	CcSEcCtD
Tapentadol—Dermatitis—Metformin—type 2 diabetes mellitus	0.00011	0.000502	CcSEcCtD
Tapentadol—Pruritus—Losartan—type 2 diabetes mellitus	0.000109	0.000501	CcSEcCtD
Tapentadol—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000109	0.0005	CcSEcCtD
Tapentadol—Headache—Metformin—type 2 diabetes mellitus	0.000109	0.000499	CcSEcCtD
Tapentadol—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000109	0.000497	CcSEcCtD
Tapentadol—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000106	0.000484	CcSEcCtD
Tapentadol—Urticaria—Ramipril—type 2 diabetes mellitus	0.000105	0.000482	CcSEcCtD
Tapentadol—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000104	0.000478	CcSEcCtD
Tapentadol—Rash—Irbesartan—type 2 diabetes mellitus	0.000103	0.000474	CcSEcCtD
Tapentadol—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000103	0.000474	CcSEcCtD
Tapentadol—Nausea—Metformin—type 2 diabetes mellitus	0.000103	0.000473	CcSEcCtD
Tapentadol—Headache—Irbesartan—type 2 diabetes mellitus	0.000103	0.000471	CcSEcCtD
Tapentadol—Dizziness—Losartan—type 2 diabetes mellitus	0.000102	0.000468	CcSEcCtD
Tapentadol—Vomiting—Losartan—type 2 diabetes mellitus	9.82e-05	0.00045	CcSEcCtD
Tapentadol—Hypersensitivity—Ramipril—type 2 diabetes mellitus	9.76e-05	0.000447	CcSEcCtD
Tapentadol—Nausea—Irbesartan—type 2 diabetes mellitus	9.75e-05	0.000447	CcSEcCtD
Tapentadol—Rash—Losartan—type 2 diabetes mellitus	9.74e-05	0.000446	CcSEcCtD
Tapentadol—Dermatitis—Losartan—type 2 diabetes mellitus	9.73e-05	0.000446	CcSEcCtD
Tapentadol—Headache—Losartan—type 2 diabetes mellitus	9.67e-05	0.000443	CcSEcCtD
Tapentadol—Asthenia—Ramipril—type 2 diabetes mellitus	9.5e-05	0.000435	CcSEcCtD
Tapentadol—Pruritus—Ramipril—type 2 diabetes mellitus	9.37e-05	0.000429	CcSEcCtD
Tapentadol—Nausea—Losartan—type 2 diabetes mellitus	9.17e-05	0.00042	CcSEcCtD
Tapentadol—Diarrhoea—Ramipril—type 2 diabetes mellitus	9.06e-05	0.000415	CcSEcCtD
Tapentadol—Dizziness—Ramipril—type 2 diabetes mellitus	8.76e-05	0.000401	CcSEcCtD
Tapentadol—Vomiting—Ramipril—type 2 diabetes mellitus	8.42e-05	0.000386	CcSEcCtD
Tapentadol—Rash—Ramipril—type 2 diabetes mellitus	8.35e-05	0.000383	CcSEcCtD
Tapentadol—Dermatitis—Ramipril—type 2 diabetes mellitus	8.34e-05	0.000382	CcSEcCtD
Tapentadol—Headache—Ramipril—type 2 diabetes mellitus	8.29e-05	0.00038	CcSEcCtD
Tapentadol—Nausea—Ramipril—type 2 diabetes mellitus	7.86e-05	0.00036	CcSEcCtD
Tapentadol—OPRK1—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.16e-06	8.09e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—APOA1—type 2 diabetes mellitus	9.16e-06	8.09e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AGT—type 2 diabetes mellitus	9.14e-06	8.08e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IRS1—type 2 diabetes mellitus	9.12e-06	8.05e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	9.1e-06	8.03e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	9.03e-06	7.98e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.99e-06	7.94e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APOE—type 2 diabetes mellitus	8.96e-06	7.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—LEP—type 2 diabetes mellitus	8.96e-06	7.91e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ALB—type 2 diabetes mellitus	8.93e-06	7.89e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC2A2—type 2 diabetes mellitus	8.91e-06	7.87e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	8.91e-06	7.87e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.86e-06	7.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.84e-06	7.81e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	8.81e-06	7.78e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	8.78e-06	7.76e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CPT1A—type 2 diabetes mellitus	8.73e-06	7.71e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTR—type 2 diabetes mellitus	8.73e-06	7.71e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—INS—type 2 diabetes mellitus	8.73e-06	7.71e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GLP1R—type 2 diabetes mellitus	8.71e-06	7.69e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCL2—type 2 diabetes mellitus	8.59e-06	7.59e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NAMPT—type 2 diabetes mellitus	8.56e-06	7.56e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3R1—type 2 diabetes mellitus	8.54e-06	7.54e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NOS3—type 2 diabetes mellitus	8.54e-06	7.54e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	8.51e-06	7.52e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HBA1—type 2 diabetes mellitus	8.51e-06	7.52e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—LIPC—type 2 diabetes mellitus	8.51e-06	7.52e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GCK—type 2 diabetes mellitus	8.51e-06	7.52e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.48e-06	7.49e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP11A1—type 2 diabetes mellitus	8.46e-06	7.47e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.45e-06	7.46e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.44e-06	7.46e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.44e-06	7.45e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	8.4e-06	7.42e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.32e-06	7.35e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC9A1—type 2 diabetes mellitus	8.31e-06	7.34e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CETP—type 2 diabetes mellitus	8.21e-06	7.25e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	8.2e-06	7.24e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—C3—type 2 diabetes mellitus	8.13e-06	7.19e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC2A2—type 2 diabetes mellitus	8.13e-06	7.18e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARG—type 2 diabetes mellitus	8.07e-06	7.13e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	8.03e-06	7.09e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	8.03e-06	7.09e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.02e-06	7.08e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.99e-06	7.06e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CPT1A—type 2 diabetes mellitus	7.96e-06	7.03e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTR—type 2 diabetes mellitus	7.96e-06	7.03e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—INS—type 2 diabetes mellitus	7.91e-06	6.99e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	7.88e-06	6.96e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	7.83e-06	6.91e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	7.83e-06	6.91e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	7.83e-06	6.91e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—type 2 diabetes mellitus	7.81e-06	6.9e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NAMPT—type 2 diabetes mellitus	7.81e-06	6.9e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	7.78e-06	6.87e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	7.76e-06	6.86e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—LIPC—type 2 diabetes mellitus	7.76e-06	6.85e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HBA1—type 2 diabetes mellitus	7.76e-06	6.85e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GCK—type 2 diabetes mellitus	7.76e-06	6.85e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.76e-06	6.85e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.74e-06	6.84e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	7.73e-06	6.83e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP11A1—type 2 diabetes mellitus	7.71e-06	6.81e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.66e-06	6.76e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.66e-06	6.76e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	7.65e-06	6.76e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—INS—type 2 diabetes mellitus	7.65e-06	6.76e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	7.64e-06	6.75e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PSMD6—type 2 diabetes mellitus	7.63e-06	6.74e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SNAP25—type 2 diabetes mellitus	7.63e-06	6.74e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SREBF1—type 2 diabetes mellitus	7.63e-06	6.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.6e-06	6.71e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC9A1—type 2 diabetes mellitus	7.57e-06	6.69e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	7.57e-06	6.69e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	7.57e-06	6.69e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	7.55e-06	6.67e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.53e-06	6.65e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CTGF—type 2 diabetes mellitus	7.49e-06	6.62e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CETP—type 2 diabetes mellitus	7.49e-06	6.61e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.49e-06	6.61e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMGCR—type 2 diabetes mellitus	7.42e-06	6.56e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.4e-06	6.54e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.4e-06	6.54e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.37e-06	6.51e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	7.32e-06	6.47e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADRA2A—type 2 diabetes mellitus	7.27e-06	6.42e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—type 2 diabetes mellitus	7.25e-06	6.41e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	7.21e-06	6.37e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.14e-06	6.31e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.03e-06	6.21e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	7.02e-06	6.2e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	7.02e-06	6.2e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	7.02e-06	6.2e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP2E1—type 2 diabetes mellitus	6.98e-06	6.17e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	6.98e-06	6.17e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PSMD6—type 2 diabetes mellitus	6.96e-06	6.15e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SREBF1—type 2 diabetes mellitus	6.96e-06	6.15e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SNAP25—type 2 diabetes mellitus	6.96e-06	6.15e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3R1—type 2 diabetes mellitus	6.94e-06	6.13e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NOS3—type 2 diabetes mellitus	6.94e-06	6.13e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC2A1—type 2 diabetes mellitus	6.9e-06	6.1e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A2—type 2 diabetes mellitus	6.9e-06	6.1e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	6.89e-06	6.09e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CTGF—type 2 diabetes mellitus	6.83e-06	6.03e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	6.83e-06	6.03e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMGCR—type 2 diabetes mellitus	6.77e-06	5.98e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.76e-06	5.97e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP3A4—type 2 diabetes mellitus	6.73e-06	5.95e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.71e-06	5.93e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.71e-06	5.93e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	6.7e-06	5.92e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	6.68e-06	5.9e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	6.68e-06	5.9e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADRA2A—type 2 diabetes mellitus	6.63e-06	5.85e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC2A4—type 2 diabetes mellitus	6.62e-06	5.85e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GCG—type 2 diabetes mellitus	6.62e-06	5.85e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.56e-06	5.79e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.5e-06	5.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—INS—type 2 diabetes mellitus	6.47e-06	5.71e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.46e-06	5.7e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	6.42e-06	5.67e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	6.37e-06	5.62e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.37e-06	5.62e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	6.35e-06	5.61e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	6.35e-06	5.61e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—type 2 diabetes mellitus	6.35e-06	5.61e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RELA—type 2 diabetes mellitus	6.32e-06	5.58e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	6.29e-06	5.56e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	6.29e-06	5.56e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.26e-06	5.53e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.25e-06	5.52e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.23e-06	5.5e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	6.19e-06	5.47e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.14e-06	5.43e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	6.14e-06	5.42e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	6.11e-06	5.39e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	6.09e-06	5.38e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	6.09e-06	5.38e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.08e-06	5.37e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	6.03e-06	5.33e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	6.03e-06	5.33e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.96e-06	5.26e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.94e-06	5.25e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.75e-06	5.08e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	5.7e-06	5.04e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.7e-06	5.04e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.7e-06	5.03e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	5.68e-06	5.02e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.67e-06	5.01e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.67e-06	5.01e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	5.66e-06	5e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.66e-06	5e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	5.6e-06	4.95e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.52e-06	4.87e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	5.44e-06	4.8e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.39e-06	4.76e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	5.34e-06	4.72e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.33e-06	4.71e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	5.29e-06	4.67e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	5.25e-06	4.63e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.25e-06	4.63e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.22e-06	4.61e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	5.22e-06	4.61e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	5.2e-06	4.59e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.2e-06	4.59e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	5.19e-06	4.59e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	5.18e-06	4.57e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	5.15e-06	4.55e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	5.11e-06	4.51e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	5.08e-06	4.49e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	5.07e-06	4.48e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.06e-06	4.47e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	5e-06	4.42e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SRC—type 2 diabetes mellitus	4.97e-06	4.39e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.96e-06	4.38e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	4.96e-06	4.38e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	4.93e-06	4.36e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	4.87e-06	4.3e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	4.87e-06	4.3e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.86e-06	4.29e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.84e-06	4.27e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	4.82e-06	4.26e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.82e-06	4.25e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.79e-06	4.23e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	4.78e-06	4.22e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	4.73e-06	4.18e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	4.68e-06	4.13e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	4.68e-06	4.13e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	4.66e-06	4.12e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	4.64e-06	4.09e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	4.62e-06	4.08e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	4.59e-06	4.05e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.55e-06	4.02e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	4.54e-06	4.01e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.5e-06	3.98e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	4.5e-06	3.97e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	4.48e-06	3.96e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	4.44e-06	3.92e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	4.44e-06	3.92e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.44e-06	3.92e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.41e-06	3.9e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	4.37e-06	3.86e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	4.35e-06	3.85e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.35e-06	3.84e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	4.3e-06	3.8e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	4.3e-06	3.8e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	4.26e-06	3.77e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	4.22e-06	3.73e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	4.2e-06	3.71e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	4.18e-06	3.69e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.09e-06	3.61e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	4.09e-06	3.61e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	4.05e-06	3.58e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	4.02e-06	3.55e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	4e-06	3.54e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	3.98e-06	3.52e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	3.97e-06	3.51e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	3.96e-06	3.5e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—type 2 diabetes mellitus	3.92e-06	3.47e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	3.92e-06	3.47e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	3.81e-06	3.37e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	3.79e-06	3.35e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.75e-06	3.31e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	3.72e-06	3.28e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.68e-06	3.25e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.52e-06	3.11e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	3.49e-06	3.08e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	3.46e-06	3.05e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	3.42e-06	3.02e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	3.41e-06	3.01e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	3.39e-06	3e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	3.34e-06	2.95e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	3.26e-06	2.88e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	3.26e-06	2.88e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—type 2 diabetes mellitus	3.19e-06	2.82e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	3.14e-06	2.77e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	3.11e-06	2.75e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.09e-06	2.73e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	3e-06	2.65e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	3e-06	2.65e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	2.98e-06	2.63e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	2.97e-06	2.63e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	2.97e-06	2.63e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.83e-06	2.5e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	2.74e-06	2.42e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	2.72e-06	2.4e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.61e-06	2.3e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	1.5e-06	1.32e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.38e-06	1.22e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	1.37e-06	1.21e-05	CbGpPWpGaD
